Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 501
Filtrar
Más filtros

Intervalo de año de publicación
1.
Rev Clin Esp (Barc) ; 2024 Oct 03.
Artículo en Inglés | MEDLINE | ID: mdl-39368774

RESUMEN

BACKGROUND: Measles is one of the most contagious infectious diseases. Spain was declared free of endemic measles transmission in 2017. However, less than half of EU/EEA countries have achieved vaccination coverage goals and measles outbreaks have been reported recently, some of them in healthcare facilities. The aim of this study was to present an outbreak in the pediatric emergency (ER) waiting room affecting a vaccinated healthcare worker. METHODS: Descriptive study of an outbreak whose transmission occurred in the pediatric ER waiting room of a tertiary level hospital on the island of Tenerife (Canary Islands) in April 2024. RESULTS: Between April 23 and May 12, 2024, four PCR-confirmed measles cases were identified, resulting in 407 contacts in healthcare center waiting rooms. One of the cases was a 26-year-old male nurse who had been correctly vaccinated with two doses of measles, mumps, and rubella vaccine during childhood. Between May 7 and 10, during his infective period, he took two two-and-a-half-hour flights and lived together with nine people during a trip. No evidence of infection has been identified among the individuals with whom he lived neither the passengers and crew of the two flights. CONCLUSIONS: In the emergency waiting room, an unvaccinated girl gave measles to two infants who were not yet old enough to be vaccinated and to a nurse who had been properly vaccinated as an infant. Despite generating more than 300 close contacts, the nurse did not infect anyone, suggesting that vaccination may help prevent both infection and transmission of measles.

2.
Rev. Fed. Centroam. Obstet. Ginecol. ; 28(2): 73-77, 30 de agosto de 2024.
Artículo en Español | LILACS-Express | LILACS | ID: biblio-1568205

RESUMEN

En marzo de 2020, la Organización Mundial de la Salud decretó la pandemia de COVID-19 y para prevenir los casos de Síndrome Respiratorio Agudo Severo y otras complicaciones una de las medidas adoptadas fue la vacunación contra el COVID-19. El virus SARS-CoV-2, responsable del COVID-19, penetra en las células huésped a través de los receptores de la enzima convertidora de angiotensina II que se expresan en diversos órganos como el útero y los ovarios. Hasta el último trimestre de 2021, se han aprobado en todo el mundo unas doce vacunas, en seis categorías diferentes, contra el COVID-19, y entre los efectos adversos se han notificado irregularidades menstruales. En varios estudios se mencionan alteraciones del ciclo menstrual tales como alteración de la duración del ciclo, aumento del flujo menstrual, dismenorrea y amenorrea de 7 a 30 días después de la administración de la última dosis de COVID-19. También se observó en estos estudios que mujeres que no presentaban irregularidades después de la primera dosis de la vacuna, empezaron a tenerlas después de la segunda dosis. En general, las anormalidades del ciclo menstrual cesan dentro de los 3 meses después de la última dosis de la vacuna y no hay un impacto definitivo sobre la fertilidad de la mujer. (provisto por Infomedic Intl)


In March 2020, the World Health Organization decreed the COVID-19 pandemic and to avoid cases of Severe Acute Respiratory Syndrome and other complications, one of the measures adopted was vaccination for COVID-19. The SARS-CoV-2 virus, responsible for COVID-19, enters host cells through angiotensin II converting enzyme receptors that are expressed in various organs such as the uterus and ovaries. Until the last quarter of 2021, around the world, about twelve vaccines were approved, in six different categories, for COVID-19 and among the adverse effects there was the report of menstrual irregularities. In several studies, changes in the menstrual cycle are mentioned, such as changes in the duration of the cycle, increased menstrual flow, dysmenorrhea and amenorrhea from 7 to 30 days after the administration of the last dose for COVID-19. It was also observed in these studies that women who did not have irregularities after the first dose of the vaccine started to have them after the second dose. In general, changes in the menstrual cycle cease within 3 months after the last dose of the vaccine and there is no definitive impact on the woman's fertility. (provided by Infomedic Intl)

3.
Pediátr. Panamá ; 53(2): 47-48, 31 de agosto de 2024.
Artículo en Español | LILACS-Express | LILACS | ID: biblio-1568222

RESUMEN

Según datos del Servicio de  Epidemiología del Hospital del Niño Doctor José Renán Esquivel (Panamá),  en los últimos 3 años, el VRS ha sido causante del 4.7 al 10.5% de todas las admisiones , siendo el 61% de los casos en menores de 1 año; la letalidad para el 2023 fue del 1.2%. Mientras, hasta agosto de 2024 hay confirmados  514 casos hospitalizados de VRS  y 10 defunciones ( letalidad +/-1.9%) (provisto por Infomedic International)


According to data from the Epidemiology Service of the  Hospital del Niño Doctor José Renán Esquivel (Panama), in the last 3 years, RSV has been the cause of 4.7 to 10.5% of all admissions, accounting for 61% of the cases. in children under 1 year of age; The fatality rate for 2023 was 1.2%. Meanwhile, until August 2024 there are 514 confirmed hospitalized cases of RSV and 10 deaths (fatality +/-1.9%) (provided by Infomedic International)

4.
Invest. educ. enferm ; 42(2): 27-44, 20240722. ilus, tab
Artículo en Inglés | LILACS, BDENF, COLNAL | ID: biblio-1567279

RESUMEN

Objective. To analyze the duties of wet nurses at the Hospital Real in Santiago de Compostela (Spain). The secondary objectives were to compare the mortality rate and distribution by parish of the foundlings under the care of the Royal House between 1803 and 1808; and to determine the origin of the Galician foundlings who participated in the Royal Philanthropic Expedition of the Smallpox Vaccine in 1803. Methods. Historiographic study that analyzed sorted and not sorted in series indirect positional and quantitative historical sources.Results. The duties of wet nurses during the studied period were to provide basic care and cultural instruction. The mortality rate of foundlings fluctuated during that period and their distribution by parish (functional unit of healthcare services at that time) was similar in those years, with a predominance in the provinces of A Coruña and Pontevedra. A total of 5 Galician foundlings from the House analyzed were part of the smallpox vaccine expedition, their names were Juan Antonio, Jacinto, Gerónimo María, Francisco Florencio and Juan Francisco. Conclusion. During the observed period the wet nurses of the Hospital Real of Santiago de Compostela were in charge of pediatric care. Wet nurses were vital in the role of keeping the foundlings alive and can be considered as one of the forerunners of the pediatric nurse profession at that time.


Objetivo. analizar las funciones que realizaban las amas de leche en el Hospital Real de Santiago de Compostela (España). Los objetivos secundarios han sido: comparar la mortalidad y distribución por parroquias de los niños expósitos a cargo de la Real Casa entre 1803 y 1808, determinar la procedencia de los niños expósitos gallegos que participaron en la Real Expedición Filantrópica de la Vacuna de la viruela en 1803. Métodos. Estudio historiográfico que analizó fuentes históricas posicionales indirectas y cuantitativas seriadas y no seriadas. Resultados. las funciones de las nodrizas durante el período de estudio eran proporcionar los cuidados básicos e instrucción cultural; la mortalidad de los expósitos sufrió oscilaciones a lo largo del período analizado. La distribución por parroquias (unidad funcional de las áreas de salud en la época) fue similar en estos años, con predominancia de las provincias de A Coruña y Pontevedra. Un total de 5 niños expósitos gallegos de la Casa analizada han participado en la expedición filantrópica de la viruela, sus nombres fueron: Juan Antonio, Jacinto, Gerónimo María, Francisco Florencio y Juan Francisco. Conclusión. Durante el período de observación, las amas de leche del Hospital Real de Santiago de Compostela realizaban cuidados pediátricos. Las nodrizas cumplieron un rol fundamental para el mantenimiento con vida de los niños expósitos y pueden ser consideradas como una de las figuras precursoras de la profesión enfermera pediátrica en la época.


Objetivo. Analisar as funções desempenhadas pelas nutrizes no Hospital Real de Santiago de Compostela (Espanha). Os objetivos secundários foram: comparar a mortalidade e distribuição por freguesia dos enjeitados responsáveis pela Casa Real entre 1803 e 1808, determinar a origem dos enjeitados galegos que participaram na Real Expedição Filantrópica da Vacina contra a Varíola em 1803. Métodos. Estudo historiográfico que analisou fontes históricas posicionais indiretas e quantitativas seriadas e não seriadas. Resultados. As funções das amas de leite durante o período do estudo eram fornecer cuidados básicos e instrução cultural; A mortalidade dos enjeitados oscilou ao longo do período analisado. A distribuição por freguesias (unidade funcional das áreas de saúde da época) foi semelhante nestes anos, com predominância das províncias da Corunha e Pontevedra. Na expedição filantrópica contra a varíola participaram um total de 5 crianças galegas da Casa analisada, os seus nomes eram: Juan Antônio, Jacinto, Gerônimo María, Francisco Florencio e Juan Francisco. Conclusão. Durante o período de observação, as nutrizes do Hospital Real de Santiago de Compostela prestaram cuidados pediátricos. As amas de leite desempenharam um papel fundamental na manutenção da vida dos enjeitados e podem ser consideradas uma das figuras precursoras da profissão de enfermagem pediátrica da época.


Asunto(s)
Humanos , Lactancia Materna , Vacuna contra Viruela , Crianza del Niño , Mortalidad Infantil , Expediciones , Nutrición Materna , Niños Huérfanos , Hospitales
5.
Bol Med Hosp Infant Mex ; 81(3): 176-181, 2024.
Artículo en Inglés | MEDLINE | ID: mdl-38941633

RESUMEN

BACKGROUND: HIV-infected children have a higher risk of presenting infections, including the hepatitis A virus (HAV). The inactivated HAV vaccine is immunogenic in immunocompetent hosts; however, there are insufficient studies on the duration of seroprotection in HIV-infected children. METHODS: An analytical cohort study was conducted. HIV-1-infected children who received the inactivated HAV vaccine (2 doses) were included. Blood samples were taken for antibody measurement, the first one 28 days after the second dose and another 7 years after the vaccination schedule. Information on viral load, immunological category, weight, height, and response to antiretroviral treatment from diagnosis to the last assessment was obtained. RESULTS: 19 patients were included, with a mean age of 12.6 years (SD ± 2.29). 58% were male. 80% of the patients presented protective immunoglobulin G antibodies against HAV 7-year post-vaccination. The antibody concentration was found to be between 13 and 80 mIU/mL (median of 80 mIU/mL). 52% showed some degree of immunosuppression. There was no statistically significant relationship between the presence of seroprotection and viral load, treatment failure, immunological category, and malnutrition. Twelve patients presented with antiretroviral treatment failure, and in 33% of them, the antibodies did not offer satisfactory seroprotection. CONCLUSION: 7-year post-vaccination, 80% of HIV-infected children maintain seroprotection titers against HAV.


INTRODUCCIÓN: Los niños infectados por el virus de la inmunodeficiencia humana (VIH) tienen mayor riesgo de presentar infecciones, incluyendo hepatitis por virus A (VHA). La vacuna inactivada contra el VHA es inmunógena en el huésped inmunocompetente. No hay estudios suficientes sobre el tiempo de seroprotección en niños infectados por el VIH. MÉTODO: Estudio de cohorte, analítico. Se incluyeron niños con infección por VIH-1 que recibieron la vacuna inactivada contra el VHA (dos dosis). Se les tomaron muestras sanguíneas para medición de anticuerpos, una 28 días después de la segunda dosis y otra 7 años después del esquema de vacunación. Se obtuvo información de carga viral, categoría inmunológica, peso y talla, y respuesta al tratamiento antirretroviral desde el diagnóstico hasta la última valoración. RESULTADOS: Se incluyeron 19 pacientes con una edad media de 12.6 años (± 2.29). El 58% fueron del sexo masculino. El 80% de los pacientes presentaron anticuerpos immunoglobulin G (IgG) contra el VHA protectores a los 7 años de la vacunación. La concentración de anticuerpos se encontró entre 13 y 80 mUI/ml (mediana: 80 mUI/ml). El 52% mostraron algún grado de inmunosupresión. No existe relación estadísticamente significativa entre la presencia de seroprotección y la carga viral, la falla al tratamiento, la categoría inmunológica ni la desnutrición. Doce pacientes presentaron falla al tratamiento antirretroviral; en el 33% de ellos los anticuerpos no ofrecían seroprotección satisfactoria. CONCLUSIONES: A 7 años posvacunación, el 80% de los niños con VIH mantienen títulos de seroprotección frente al VHA.


Asunto(s)
Infecciones por VIH , Anticuerpos de Hepatitis A , Vacunas contra la Hepatitis A , Hepatitis A , Carga Viral , Humanos , Masculino , Infecciones por VIH/tratamiento farmacológico , Infecciones por VIH/inmunología , Niño , Vacunas contra la Hepatitis A/administración & dosificación , Vacunas contra la Hepatitis A/inmunología , Femenino , Anticuerpos de Hepatitis A/sangre , Adolescente , Hepatitis A/prevención & control , Hepatitis A/inmunología , Estudios de Cohortes , Factores de Tiempo , Estudios de Seguimiento , Inmunoglobulina G/sangre , Inmunoglobulina G/inmunología , Vacunas de Productos Inactivados/inmunología , Vacunas de Productos Inactivados/administración & dosificación
6.
An Pediatr (Engl Ed) ; 100(6): 438-447, 2024 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-38851979

RESUMEN

The flu is a constant threat that can sometimes cause severe forms of disease. The highest incidence rates by age group occur in children under 15 years of age, especially in those under 5 years, in whom the rate of hospitalization is also similar to the population aged 65 years and older. In addition, children are the main transmitters of the infection. In Spain, 5 influenza vaccines are authorized for the paediatric age group: three inactivated tetravalent vaccines harvested from fertilised eggs, one tetravalent inactivated vaccine obtained from cell cultures and one attenuated tetravalent vaccine for intranasal administration, which will become trivalent in the 2024-2025 season by excluding the B Yamagata lineage as recommended by the WHO. The CAV-AEP recommends systematic vaccination in children aged 6-59 months, children and adolescents belonging to risk groups, people who can transmit the flu to groups at risk of complicated flu, and household contacts or close family of infants under 6 months. From 2 years of age, the intranasal attenuated vaccine is preferred due to its greater acceptability and thus contribution to greater vaccination coverage. The CAV-AEP also considers that vaccination against influenza of healthy children and adolescents aged 5-18 years is advisable, as it provides individual protection and promotes protection at the family and community levels. It is especially important to vaccinate all health care professionals against influenza as well as pregnant women at any time during pregnancy.


Asunto(s)
Vacunas contra la Influenza , Gripe Humana , Vacunación , Humanos , Vacunas contra la Influenza/administración & dosificación , Gripe Humana/prevención & control , Niño , Adolescente , Preescolar , España/epidemiología , Lactante , Vacunación/estadística & datos numéricos , Estaciones del Año , Femenino
7.
RECIIS (Online) ; 18(2)abr.-jun. 2024.
Artículo en Portugués | LILACS, ColecionaSUS | ID: biblio-1561816

RESUMEN

Neste artigo, analisamos as temáticas, os posicionamentos, as formas expressivas, os atores legitimados e os recursos visuais e sonoros empregados na produção de 482 vídeos sobre vacinas, publicados de 2020 a 2022 na plataforma de vídeos curtos Kwai. A partir de análise temática e de análise de conteúdo, identificamos que os vídeos apresentaram, em sua maioria, posicionamento favorável ou neutro em relação às vacinas e que ressaltaram as experiências pessoais com a vacinação. Não obstante, utilizaram sobretudo um tom hu-morístico no tratamento do assunto, com potencial desinformativo quanto aos efeitos colaterais das vacinas. Concluímos assim que, por um lado, o Kwai tem sido utilizado para expressão de experiências positivas com a vacinação, que podem estimular a adesão aos imunizantes, mas, por outro, tem sido também espaço para a circulação de percepções negativas e temores que podem suscitar dúvidas quanto à segurança das vacinas.


In this article, we analyze the themes, positions, expressive forms, legitimized actors, and both visual and sound resources used in the production of 482 videos about vaccines, published from 2020 to 2022 on the short video platform Kwai. Based on thematic analysis and content analysis, we identified that the videos predominantly presented a favorable or neutral stance toward vaccines and that they highlighted personal experiences with immunization. However, they mainly used a humorous tone when dealing with the subject, thereby potentially disseminating misinformation regarding the adverse effects of vaccines. We thus conclude that, on the one hand, Kwai has been used to express positive experiences with vaccination, which can stimulate adherence to vaccinations, but, on the other hand, it has also been a space for the circulation of negative perceptions and fears that can raise doubts regarding the safety of vaccines.


En este artículo, analizamos los temas, posiciones, formas expresivas, actores legitimados y recursos visuales y sonoros utilizados en la producción de 482 videos sobre vacunas publicados de 2020 a 2022 en la plataforma de videos cortos Kwai. A partir del análisis temático y de contenido, identificamos que los videos presentaban, en su mayoría, una posición favorable o neutral con relación a las vacunas y que destacaban experiencias per-sonales con la vacunación. Sin embargo, al abordar el tema, utilizaron, principalmente, un tono humorístico, con potencial desinformativo sobre los efectos secundarios de las vacunas. De ese modo, concluimos que, por un lado, el Kwai tiene sido utilizado para expresar experiencias positivas con la vacunación que pueden estimular la adhesión a las vacunas, pero, por otro lado, también tiene sido un espacio para la circulación de percepciones negativas y miedos que pueden plantear dudas sobre la seguridad de las vacunas.


Asunto(s)
Vacunas , Difusión de la Información , Redes Sociales en Línea , COVID-19 , Desinformación , Brasil , Inmunización , Seguridad Computacional , Comunicación , Difusión por la Web como Asunto , Difusión por la Web , Red Social , Análisis de Redes Sociales
8.
Bol. méd. Hosp. Infant. Méx ; 81(3): 176-181, may.-jun. 2024. tab, graf
Artículo en Inglés | LILACS-Express | LILACS | ID: biblio-1568905

RESUMEN

Abstract Background: HIV-infected children have a higher risk of presenting infections, including the hepatitis A virus (HAV). The inactivated HAV vaccine is immunogenic in immunocompetent hosts; however, there are insufficient studies on the duration of seroprotection in HIV-infected children. Methods: An analytical cohort study was conducted. HIV-1-infected children who received the inactivated HAV vaccine (2 doses) were included. Blood samples were taken for antibody measurement, the first one 28 days after the second dose and another 7 years after the vaccination schedule. Information on viral load, immunological category, weight, height, and response to antiretroviral treatment from diagnosis to the last assessment was obtained. Results: 19 patients were included, with a mean age of 12.6 years (SD ± 2.29). 58% were male. 80% of the patients presented protective immunoglobulin G antibodies against HAV 7-year post-vaccination. The antibody concentration was found to be between 13 and 80 mIU/mL (median of 80 mIU/mL). 52% showed some degree of immunosuppression. There was no statistically significant relationship between the presence of seroprotection and viral load, treatment failure, immunological category, and malnutrition. Twelve patients presented with antiretroviral treatment failure, and in 33% of them, the antibodies did not offer satisfactory seroprotection. Conclusion: 7-year post-vaccination, 80% of HIV-infected children maintain seroprotection titers against HAV.


Resumen Introducción: Los niños infectados por el virus de la inmunodeficiencia humana (VIH) tienen mayor riesgo de presentar infecciones, incluyendo hepatitis por virus A (VHA). La vacuna inactivada contra el VHA es inmunógena en el huésped inmunocompetente. No hay estudios suficientes sobre el tiempo de seroprotección en niños infectados por el VIH. Método: Estudio de cohorte, analítico. Se incluyeron niños con infección por VIH-1 que recibieron la vacuna inactivada contra el VHA (dos dosis). Se les tomaron muestras sanguíneas para medición de anticuerpos, una 28 días después de la segunda dosis y otra 7 años después del esquema de vacunación. Se obtuvo información de carga viral, categoría inmunológica, peso y talla, y respuesta al tratamiento antirretroviral desde el diagnóstico hasta la última valoración. Resultados: Se incluyeron 19 pacientes con una edad media de 12.6 años (± 2.29). El 58% fueron del sexo masculino. El 80% de los pacientes presentaron anticuerpos immunoglobulin G (IgG) contra el VHA protectores a los 7 años de la vacunación. La concentración de anticuerpos se encontró entre 13 y 80 mUI/ml (mediana: 80 mUI/ml). El 52% mostraron algún grado de inmunosupresión. No existe relación estadísticamente significativa entre la presencia de seroprotección y la carga viral, la falla al tratamiento, la categoría inmunológica ni la desnutrición. Doce pacientes presentaron falla al tratamiento antirretroviral; en el 33% de ellos los anticuerpos no ofrecían seroprotección satisfactoria. Conclusiones: A 7 años posvacunación, el 80% de los niños con VIH mantienen títulos de seroprotección frente al VHA.

9.
Enferm. foco (Brasília) ; 15: 1-5, maio. 2024. ilus, tab
Artículo en Portugués | LILACS, BDENF | ID: biblio-1554052

RESUMEN

Objetivo: Fomentar o debate acerca da ordenação do plano de vacinação nacional, considerando os aspectos organizacionais entre união, estados e municípios. Métodos: Revisão de literatura, tendo como base os periódicos Cientific Electronic Library Online (SCIELO), Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) e Biblioteca Virtual de Saúde (BVS), usando como descritores: Pandemia, Vacina e Plano de Imunização. Com essa busca foram encontradas, inicialmente, 48 publicações. Após a realização da análise, foram incluídos 11 artigos científicos na revisão. Os textos foram submetidos à análise de conteúdo semântica. Resultados: Foram levantadas duas categorias: estratégias de combate a pandemia do covid-19 no Brasil, e a manipulação da sociedade civil e a desordem da cobertura vacinal. Conclusão: as reflexões aqui apresentadas podem contribuir para que os profissionais de enfermagem desenvolvam uma postura reflexiva frente a demanda vacinal, processo de planejamento e percepções da sociedade civil, podendo desencadear uma melhora na preparação para a educação em saúde. (AU)


Objective: To encourage the debate about the ordering of the national vaccination plan, considering the organizational aspects between the union, states and municipalities. Methods: Literature review, based on scientific journals Electronic Library Online (SCIELO), Coordination for the Improvement of Higher Education Personnel (CAPES) and Virtual Health Library (VHL), using as descriptors: Pandemia, Vaccine and Immunization Plan. With this search, 48 publications were initially found. After the analysis, 11 scientific articles were included in the review. The texts were subjected to semantic content analysis. Results: Two categories were raised: strategies to combat the covid-19 pandemic in Brazil, and the manipulation of civil society and the disorder of vaccination coverage. Conclusion: The reflections presented here can contribute for nursing professionals to develop a reflexive posture in face of the vaccine demand, planning process and civil society perceptions, which can trigger an improvement in the preparation for health education. (AU)


Objetivo: Fomentar el debate sobre la ordenación del plan nacional de vacunación, considerando los aspectos organizativos entre sindicato, estados y municipios. Métodos: Revisión de la literatura, con base en revistas científicas Biblioteca Electrónica en Línea (SCIELO), Coordinación para el Perfeccionamiento del Personal de Educación Superior (CAPES) y Biblioteca Virtual en Salud (BVS), utilizando como descriptores: Pandemia, Vacuna y Plan de Inmunización. Con esta búsqueda se encontraron inicialmente 48 publicaciones. Después del análisis, se incluyeron 11 artículos científicos en la revisión. Los textos fueron sometidos a análisis de contenido semántico. Resultados: Se plantearon dos categorías: estrategias para combatir la pandemia de covid-19 en Brasil y la manipulación de la sociedad civil y el desorden de la cobertura de vacunación. Conclusión: Las reflexiones aquí presentadas pueden contribuir para que los profesionales de enfermería desarrollen una postura reflexiva ante la demanda de vacunas, el proceso de planificación y las percepciones de la sociedad civil, lo que puede desencadenar una mejora en la preparación para la educación en salud. (AU)


Asunto(s)
Pandemias , Vacunas , Programas de Inmunización
10.
Med. clín. soc ; 8(1)abr. 2024.
Artículo en Español | LILACS-Express | LILACS | ID: biblio-1550541

RESUMEN

Introducción: La pandemia del COVID-19 ha provocado cambios que afectan a los sistemas sanitarios y al enfoque de las enfermedades infecciosas en todo el mundo. La demanda de vacunas contra el COVID-19 se encuadra en un espectro que va desde el rechazo hasta la demanda, con una aceptación pasiva en el medio. Objetivo: Determinar la adherencia de los adultos a la vacunación contra la COVID-19. Chauria-Caballero, Paraguay 2022. Metodología: Estudio observacional, descriptivo, de corte transversal, con enfoque cuantitativo. El muestreo fue no probabilístico por conveniencia. La muestra estuvo conformada por un total de 225 adultos; los datos fueron recabados por medio de una encuesta elaborada por la investigadora, los datos fueron procesados con el software EPI INFO. Resultados: La mayoría de los sujetos de estudio se vacunaron, y hubo adherencia de la población a la vacuna contra la COVID-19 en un 93 %; diversos factores influyeron en las decisiones de estos; el porcentaje de adultos no vacunados mencionan como motivos su desconfianza (69 %) y el miedo/temor a la vacunación (31 %). Discusión: El estudio encontró una alta adherencia en general, la gran mayoría de los participantes vacunados contra COVID-19, porcentajes significativos se reportaron en Chile, China y Catar, cifras muy altas con relación a la aceptación de la vacuna a nivel país, teniendo una cobertura con un porcentaje mayor a la mitad con al menos una dosis.


Introduction: The coronavirus disease (COVID-19) pandemic has caused changes that affect health systems and the approach to infectious diseases worldwide. The demand for COVID-19 vaccines falls on a spectrum from rejection to demand, with passive acceptance in between. Objective: To determine the adherence of adults to vaccination against COVID-19. Chauria-Caballero, Paraguay 2022. Methods: This was an observational, descriptive, cross-sectional study using a quantitative approach. For convenience, the sampling was non-probabilistic. The sample comprised of 225 adults. The data were collected through a survey elaborated by the researcher, and the data were processed using EPI INFO software. Results: The majority of the study subjects were vaccinated, and there was 93% adherence of the population to the COVID-19 vaccine. Various factors influenced their decisions; the percentage of unvaccinated adults mentioned their distrust (69%) and fear of vaccination (31%). Discussion: The study found high adherence in general, the vast majority of participants were vaccinated against COVID-19, with significant percentages reported in Chile, China, and Qatar, very high figures in relation to the acceptance of the vaccine at the country level, with coverage of more than half with at least one dose.

11.
Arch. argent. pediatr ; 122(2): e202310144, abr. 2024. tab, ilus
Artículo en Inglés, Español | LILACS, BINACIS | ID: biblio-1537966

RESUMEN

El dengue es una enfermedad viral transmitida por la picadura del mosquito Aedes aegypti. El comportamiento del dengue en Argentina es epidémico; la mayoría de los casos se observan en los meses de mayor temperatura. Hasta la semana epidemiológica (SE) 20/2023, se registraron en Argentina 106 672 casos; se vieron afectadas 18 de las 24 provincias que conforman el país. Dentro de los principales grupos de riesgo, se incluyen los menores de 2 años. Reconocer los signos, síntomas e identificar los factores de riesgo es fundamental para el manejo de casos con mayor riesgo de gravedad. Presentamos el caso de una paciente de 32 días de vida que se internó por síndrome febril sin foco, con diagnósticos diferenciales de meningitis viral y sepsis, evolucionó con leucocitosis, plaquetopenia, hipoalbuminemia, asociado a exantema y edemas. Se llegó al diagnóstico de dengue por la clínica, epidemiologia e IgM positiva.


Dengue fever is a viral disease transmitted by the Aedes aegypti mosquitoes. In Argentina, dengue fever is an epidemic disease; most cases are reported during the hot months.Until epidemiological week (EW) 20/2023, 106 672 cases were reported across 18 of the 24 provinces of Argentina. Children younger than 2 years are among the main groups at risk. Recognizing signs and symptoms and identifying risk factors is fundamental for the management of cases at a higher risk of severity. Here we describe the case of a 32-day-old female patient who was hospitalized due to febrile syndrome without a source, who had a differential diagnosis of viral meningitis and sepsis and progressed to leukocytosis, thrombocytopenia, hypoalbuminemia in association with rash and edema. The diagnosis of dengue fever was established based on clinical, epidemiological, and positive IgM data.


Asunto(s)
Humanos , Animales , Femenino , Lactante , Aedes , Dengue/complicaciones , Dengue/diagnóstico , Dengue/epidemiología , Argentina , Factores de Riesgo , Diagnóstico Diferencial
12.
Enferm Infecc Microbiol Clin (Engl Ed) ; 42(3): 140-145, 2024 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-38342648

RESUMEN

INTRODUCTION: Influenza poses a significant burden in terms of morbidity and mortality, with vaccination being one of the most effective measures for its prevention. Therefore, the aim of this study is to determine the effectiveness of the influenza vaccine in preventing cases of severe influenza in patients admitted to a tertiary hospital during the 2022/23 season. METHODS: Case-control study. All hospitalised patients with a positive result in an RT-PCR for influenza were included. Those who met the criteria for a severe case (pneumonia, sepsis, multi-organ failure, admission to ICU or exitus) were considered cases. Those who did not meet these criteria were considered controls. Vaccine effectiveness (VE) to prevent severe cases and its 95% confidence interval were calculated. RESULTS: A total of 403 patients were admitted with confirmed influenza. Of these, 98 (24.3%) developed severe influenza. Of the total, 50.6% were men and 47.1% were over 65 years of age. VE adjusted for influenza type, age and certain comorbidities was 40.6% (-21.9 to 71.1). In a segmented analysis, influenza vaccine was effective in preventing severe cases in all categories. It was particularly relevant in the 65+ age group (VEa = 60.9%; -2.0 to 85.0) and in patients with influenza A (VEa = 56.7%; 1.5-80.9). CONCLUSION: Influenza vaccination markedly reduced the occurrence of severe cases of influenza in hospitalised patients, therefore, it remains the main strategy to reduce morbidity and mortality and associated costs.


Asunto(s)
Vacunas contra la Influenza , Gripe Humana , Masculino , Humanos , Femenino , Gripe Humana/epidemiología , Gripe Humana/prevención & control , Estudios de Casos y Controles , Estaciones del Año , Vacunación
13.
Rev Clin Esp (Barc) ; 224(4): 197-203, 2024 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-38423384

RESUMEN

AIM: To study the prevalence of neutralizing antibodies in healthcare workers and healthcare support personnel after the administration of the second dose of the BNT162b2 vaccine (Pfizer-BioNTech). MATERIALS AND METHODS: In December 2021, we undertook a study in the Health Department in Orihuela, Alicante (Spain), which consists of 1500 workers. We collected demographic variables about the study participants, and we performed a "point-of-care" immunochromatography test to measure the presence of neutralizing antibodies (OJABIO® SARS-CoV-2 Neutralizing Antibody Detection Kit, manufactured by Wenzhou OJA Biotechnology Co., Ltd. Wenzhou, Zhejiang, China) before the administration of the third dose of the vaccine. RESULTS: We obtained complete information about 964 (64%) workers, which consisted of 290 men and 674 women. The average age was 45,8 years (min. 18, max. 68) and the average time since the last dose of the vaccine was 40,5 weeks (min. 1,71, max. 47,71). A total of 131 participants (13,5%) had suffered infection by SARS-CoV-2 confirmed using RT-PCR. The proportion of participants who showed presence of neutralizing antibodies was 38,5%. In the multivariable analysis, the time since the last dose of the vaccine (aOR week: 1,07; 95%CI: 1,04; 1,09) and previous infection by SARS-CoV-2 (aOR: 3,7; 95CI: 2,39; 5,63) showed a statistically significant association with the presence of neutralizing antibodies. CONCLUSIONS: The time since the administration of the last dose of the vaccine and the previous infection by SARS-CoV-2 determined the presence of neutralizing antibodies in 38,5% of the healthcare workers and support workers.


Asunto(s)
COVID-19 , Vacunas , Masculino , Humanos , Femenino , SARS-CoV-2 , Prevalencia , España/epidemiología , Vacuna BNT162 , COVID-19/diagnóstico , COVID-19/epidemiología , COVID-19/prevención & control , Personal de Salud , Anticuerpos Neutralizantes , Pruebas Serológicas , Prueba de COVID-19
14.
Gastroenterol Hepatol ; 47(7): 750-758, 2024.
Artículo en Inglés, Español | MEDLINE | ID: mdl-38219960

RESUMEN

OBJECTIVE: The recommendations of the Spanish Ministry of Health on vaccination in risk groups include mesalazine among the treatments with a possible negative effect on its effectiveness. However, this is not the recommendation of most experts. Our objective was to evaluate the effect of mesalazine on the humoral response to the SARS-CoV-2 vaccine in patients with inflammatory bowel disease (IBD). METHODS: VACOVEII is a Spanish, prospective, multicenter study promoted by GETECCU, which evaluates the effectiveness of the SARS-CoV-2 vaccine in patients with IBD. This study includes IBD patients who have recieved the full vaccination schedule and without previous COVID-19 infection. Seroconversion was set at 260BAU/mL (centralized determination) and was assessed 6 months after full vaccination. In this subanalysis of the study, we compare the effectiveness of the vaccine between patients treated with mesalazine and patients without treatment. RESULTS: A total of 124 patients without immunosuppressive therapy were included, of which 32 did not receive any treatment and 92 received only mesalazine. Six months after full vaccination, no significant differences are observed in the mean concentrations of IgG anti-S between both groups. In the multivariate analysis, antibody titers were independently associated with the use of mRNA vaccines and with SARS-CoV-2 infection. CONCLUSION: Mesalazine does not have a negative effect on the response to SARS-CoV-2 vaccines in IBD patients.


Asunto(s)
Antiinflamatorios no Esteroideos , Vacunas contra la COVID-19 , COVID-19 , Enfermedades Inflamatorias del Intestino , Mesalamina , Humanos , Mesalamina/uso terapéutico , Femenino , Estudios Prospectivos , Masculino , Vacunas contra la COVID-19/inmunología , Enfermedades Inflamatorias del Intestino/tratamiento farmacológico , Persona de Mediana Edad , Adulto , Antiinflamatorios no Esteroideos/uso terapéutico , COVID-19/prevención & control , COVID-19/inmunología , Anticuerpos Antivirales/sangre , Vacunación , Anciano , Seroconversión , Eficacia de las Vacunas , SARS-CoV-2/inmunología
15.
Enferm Infecc Microbiol Clin (Engl Ed) ; 42(3): 152-157, 2024 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-37487765

RESUMEN

BCGitis is a rare complication after intravesical administration of Bacillus Calmette-Guérin for high-grade superficial bladder cancer and carcinoma in situ. May cause vascular involvement. We present 2 cases and a review of the literature of the case reports pubished on the 10 years prior to April of 2022, when this proyect was finished, which described a case of aortoiliac mycotic aneurysm after receiving this treatment. Of the 51 cases included (49 revised and 2 original), 100% were men, 82% were older than 65 years. The median latency period was 15 months (IQR 18). The most frequent location was the abdominal aorta, rupture occurred in 45,1% of patients. The most frequent symptom was abdominal or lumbar pain (61%), followed by general syndrome (49%). In 39,2% cases, it was associated with retroperitoneal abscesess. Attributable mortality was 13,6%. BCGitis should be included in the differential diagnosis in patients who have received BCG therapy and present vascular involvement, even years after being treated.


Asunto(s)
Aneurisma Infectado , Mycobacterium bovis , Neoplasias de la Vejiga Urinaria , Humanos , Masculino , Aneurisma Infectado/etiología , Aneurisma Infectado/diagnóstico , Neoplasias de la Vejiga Urinaria/patología , Neoplasias de la Vejiga Urinaria/terapia , Anciano
16.
Enferm Infecc Microbiol Clin (Engl Ed) ; 42(4): 187-194, 2024 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-36737369

RESUMEN

BACKGROUND: This study compares the severity of SARS-CoV-2 infections caused by Alpha, Delta or Omicron variants in periods of co-circulation in Spain, and estimates the variant-specific association of vaccination with severe disease. METHODS: SARS-CoV-2 infections notified to the national epidemiological surveillance network with information on genetic variant and vaccination status were considered cases if they required hospitalisation or controls otherwise. Alpha and Delta were compared during June-July 2021; and Delta and Omicron during December 2021-January 2022. Adjusted odds ratios (aOR) were estimated using logistic regression, comparing variant and vaccination status between cases and controls. RESULTS: We included 5,345 Alpha and 11,974 Delta infections in June-July and 5,272 Delta and 10,578 Omicron in December-January. Unvaccinated cases of Alpha (aOR: 0.57; 95% CI: 0.46-0.69) or Omicron (0.28; 0.21-0.36) had lower probability of hospitalisation vs. Delta. Complete vaccination reduced hospitalisation, similarly for Alpha (0.16; 0.13-0.21) and Delta (June-July: 0.16; 0.14-0.19; December-January: 0.36; 0.30-0.44) but lower from Omicron (0.63; 0.53-0.75) and individuals aged 65+ years. CONCLUSION: Results indicate higher intrinsic severity of the Delta variant, compared with Alpha or Omicron, with smaller differences among vaccinated individuals. Nevertheless, vaccination was associated to reduced hospitalisation in all groups.


Asunto(s)
COVID-19 , Humanos , COVID-19/epidemiología , COVID-19/prevención & control , SARS-CoV-2 , Hospitalización , Vacunación
17.
Enferm Infecc Microbiol Clin (Engl Ed) ; 42(4): 172-178, 2024 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-37085445

RESUMEN

INTRODUCTION: The 13-valent pneumococcal conjugate vaccine (PCV13) universal vaccination programme was introduced in December 2016 in Andalusia. METHODS: A cross-sectional study was conducted on the molecular epidemiology of pneumococcal nasopharyngeal colonization. A total of 397 healthy children were recruited from primary healthcare centres in Seville for the periods 1/4/2018 to 28/2/2020 and 1/11/2021 to 28/2/2022 (PCV13 period). Data from a previous carriage study conducted among healthy and sick children from 1/01/2006 to 30/06/2008 (PCV7 period), were used for comparison of serotype/genotype distributions and antibiotic resistance rates. RESULTS: Overall, 76 (19%) children were colonized with S. pneumoniae during the PCV13 period and there were information available from 154 isolates collected during the PCV7 period. Colonization with PCV13 serotypes declined significantly in the PCV13 period compared with historical controls (11% vs 38%, p = 0.0001), being serotypes 19F (8%), 3 (1%) and 6B (1%) the only circulating vaccine types. Serotypes 15B/C and 11A were the most frequently identified non-PCV13 serotypes during the PCV13 period (14% and 11%, respectively); the later one increased significantly between time periods (p = 0.04). Serotype 11A was exclusively associated in the PCV13 period with ampicillin-resistant variants of the Spain9V-ST156 clone (ST6521 and genetically related ST14698), not detected in the preceding period. CONCLUSIONS: There was a residual circulation of vaccine types following PCV13 introduction, apart from serotype 19F. Serotype 11A increased between PCV13 and PCV7 periods due to emergence and clonal expansion of ampicillin-resistant genotype ST6521.


Asunto(s)
Infecciones Neumocócicas , Niño , Humanos , Infecciones Neumocócicas/epidemiología , Infecciones Neumocócicas/prevención & control , Estudios Transversales , Epidemiología Molecular , España/epidemiología , Portador Sano/epidemiología , Streptococcus pneumoniae/genética , Ampicilina , Programas de Inmunización
18.
Cad. Saúde Pública (Online) ; 40(4): e00120023, 2024.
Artículo en Portugués | LILACS-Express | LILACS | ID: biblio-1557406

RESUMEN

Resumo: A inovação é um elemento fundamental para o desenvolvimento e crescimento, mas constituída por um processo demorado de acúmulo de conhecimento. Uma das formas de acelerar tal processo é por meio da transferência de tecnologia. Este artigo mapeou as particularidades da transferência de tecnologia para a vacina contra COVID-19, celebrado entre a AstraZeneca e o Instituto de Tecnologia em Imunobiológicos (Bio-Manguinhos), Fundação Oswaldo Cruz, bem como reconheceu os seus facilitadores, seus entraves e suas lacunas. Para tanto, foi realizada uma análise desde a etapa da seleção do parceiro mais adequado até a incorporação da nova tecnologia. A metodologia utilizada se baseou em uma ampla revisão bibliográfica sobre o tema, aliada ao estudo de caso. Os resultados apontaram que, apesar de muitas ações ainda precisarem ser realizadas para que os ganhos de capacidade tecnológica sejam potencializados, as lições aprendidas com o processo de transferência de tecnologia servirão de aprendizado e serão utilizadas nos acordos futuros e em andamento.


Resumen: La innovación es un elemento fundamental para el desarrollo y el crecimiento, pero consiste en un proceso de acumulación de conocimiento que requiere mucho tiempo. Una de las formas de acelerar este proceso es mediante la transferencia de tecnología. Este artículo mapeó las particularidades del proceso de transferencia de tecnología para la vacuna contra la COVID-19, celebrado entre AstraZeneca y el Instituto de Tecnología en Inmunobiológicos (Bio-Manguinhos), Fundación Oswaldo Cruz, además de reconocer los facilitadores, obstáculos y brechas. Para ello se realizó un análisis, desde la etapa de selección del socio más adecuado hasta la incorporación de la nueva tecnología. La metodología utilizada se basó en una amplia revisión bibliográfica sobre el tema, combinada con el estudio de caso. Los resultados mostraron que, si bien aún es necesario llevar a cabo muchas acciones para maximizar las ganancias de capacidad tecnológica, las lecciones aprendidas del proceso de transferencia de tecnología servirán como lecciones y se utilizarán en acuerdos futuros y en curso.


Abstract: Innovation is an essential element for development and growth, but it consists of a long process of knowledge accumulation, so technology transfer is used to accelerate this process. This study mapped the particularities of the technology transfer process for the COVID-19 vaccine between AstraZeneca and the Institute of Technology in Immunobiologicals (Bio-Manguinhos), Oswaldo Cruz Foundation, and identified enablers, obstacles, and gaps. Our analysis investigated the process from selection of the most suitable partner to incorporation of the new technology based on a comprehensive literature review on this topic, combined with a case study. The results showed that, although many actions still have to be performed to maximize technology capacity gains, the lessons learned from the technology transfer process will be used in future and ongoing agreements.

19.
Epidemiol. serv. saúde ; 33: e2023895, 2024. tab, graf
Artículo en Inglés | LILACS-Express | LILACS | ID: biblio-1557745

RESUMEN

Abstract Objective: To analyze the temporal trend of human papillomavirus (HPV) vaccination coverage among the female population aged 10 to 14 years, living in the state of Goiás, Brazil, between 2014 and 2022. Methods: This was an ecological time series study using data from the Brazilian National Health System Information Technology Department (Departamento de Informática do Sistema Único de Saúde - DATASUS); the annual vaccination coverage rate was calculated based on the number of second doses administered; the trend of the rates was analyzed using the Prais-Winsten model. Results: A total of 407,217 second doses of the quadrivalent HPV vaccine were administered to the female population aged 10-14 years, with annual vaccination coverage rates ranging from 12.3% (2019) to 30.0% (2015), and an annual percentage change (APC) of 0.7% (95%CI 0.9; 0.2; p-value = 0.030). Conclusion: In Góias state, the quadrivalent HPV vaccine coverage rate was below the national target (80%), showing a stationary trend in the time series.


Resumen Objetivo: Analizar la tendencia temporal de la cobertura de la vacuna contra el virus del papiloma humano (VPH), en la población femenina en Goiás, Brasil, entre 2014 y 2022. Métodos: Estudio de serie temporal con datos del Departamento de Informática del Sistema Único de Salud (Datasus); la tasa de cobertura vacunal anual fue calculada por el número de segundas dosis administradas y para el análisis de tendencias se utilizó Prais-Winsten. Resultados: Se administraron 407.217 segundas dosis de la vacuna tetravalente contra el VPH en la población femenina de 10 a 14 años en Goiás, con tasas de cobertura vacinal anual variando entre 12,3% (2019) y 30,0% (2015), y una variación porcentual anual (VPA) de 0,7% (IC95% 0,9;0,2; p-valor = 0,030). Conclusión: La tasa de cobertura de la vacuna tetravalente contra el VPH en Goiás quedó por debajo de la meta nacional (80%), con tendencia estacionaria en la serie temporal.


Resumo Objetivo: Analisar a tendência temporal da cobertura da vacina contra o papilomavírus humano (human papillomavirus, ou HPV), na população feminina com idade de 10 a 14 anos, residente no estado de Goiás, Brasil, entre 2014 e 2022. Métodos: Estudo ecológico de série temporal com dados obtidos do Departamento de Informática do Sistema Único de Saúde (Datasus); calculou-se a taxa de cobertura vacinal anual considerando-se o número de segundas doses administradas; a tendência das taxas foi analisada utilizando-se o modelo de Prais-Winsten. Resultados: Foram aplicadas 407.217 segundas doses da vacina quadrivalente contra HPV na população feminina de 10-14 anos, com taxas de cobertura vacinal anual a variar entre 12,3% (2019) e 30,0% (2015), e uma variação percentual anual (VPA) de 0,7% (IC95% 0,9;0,2; p-valor = 0,030). Conclusão: Em Goiás, a taxa de cobertura da vacina quadrivalente contra HPV esteve aquém da meta nacional (80%), com tendência estacionária da série temporal.

20.
Repert. med. cir ; 33(2): 186-190, 2024. tab
Artículo en Español | LILACS, COLNAL | ID: biblio-1561106

RESUMEN

Introducción: parte esencial del manejo y control de la pandemia por SARS-CoV-2 ha sido la vacunación. Sin embargo, las sales de aluminio usadas en las vacunas para potenciar el sistema inmune, pueden asociarse con el síndrome autoinmune/autoinflamatorio inducido por adyuvantes (ASIA). Esta condición se ha relacionado con otros factores, como agentes infecciosos, implantes de silicona e inoculación de aceites minerales. Hay poca información acerca de enfermedades endocrinas autoinmunes y ASIA después de la vacunación para SARS-CoV-2. Objetivo: reportar los casos relacionados con enfermedad tiroidea posterior a la vacunación para COVID-19, en pacientes que asistieron a la consulta de endocrinología en la clínica Imbanaco, Cali, Colombia, en 2021. Métodos: descripción clínica, de laboratorio e imágenes de 8 pacientes que acudieron a la consulta de endocrinología. Resultados y discusión: 87.5% eran de sexo femenino de 46.8 ± 10 años, el tiempo entre la aplicación de la vacuna y la aparición de los síntomas fue 13.8 días y la vacuna más relacionada fue Pfizer/BioNTech seguida por Sinovac-CoronaVac y AstraZeneca/AZD1222. La presentación de tiroiditis subaguda estuvo presente en el (37.5%), enfermedad de Graves (37.5%), tiroiditis silente (12.5%) e hipotiroidismo (12.5%). Los síntomas más comunes fueron mialgias y palpitaciones. El hallazgo ecográfico más común fue tiroiditis subaguda. Conclusiones: en esta seria de casos, reportamos una relación entre la vacunación y la aparición de enfermedad tiroidea por SARS-CoV-2. dado que estos eventos son motivo de controversia, serán necesarios otros estudios que ayuden a establecer si existe o no causalidad


Introduction: Vaccines have been an essential part of the SARS-CoV-2 pandemic management and control. However, aluminum salts in vaccines, used to enhance the immune response, may be associated with autoimmune/inflammatory syndrome induced by adjuvants (ASIA). This syndrome has been linked to other factors, such as infectious agents, silicone implants, and mineral oil inoculation. Data on autoimmune endocrine disorders and ASIA following SARS-CoV-2 vaccination is scant. Objective: to report cases of thyroid disorders following COVID-19 vaccination, in patients who attended the endocrinology clinic at Clínica Imbanaco, Cali, Colombia, in 2021. Methods: clinical, laboratory and imaging description of 8 patients who attended the endocrinology service. Results and discussion: 87.5% were females, aged 46.8 ± 10 years. Time between vaccine administration and symptoms onset was 13.8 days and the most related vaccine was the Pfizer/BioNTech vaccine followed by Sinovac-CoronaVac and AstraZeneca/AZD1222 vaccines. Subacute thyroiditis presented in 37.5%, Graves ́ disease in 37.5%, silent thyroiditis in 12.5% and hypothyroidism in 12.5%. Myalgias and palpitations were the most common symptoms. Subacute thyroiditis was the most common ultrasound finding. Conclusions: our case series evidences a relationship between thyroid disease and SARS-CoV-2 vaccination. Given controversy remains, further studies will be necessary to establish causality.


Asunto(s)
Humanos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA